Skip to main content

Advertisement

Table 4 Participant Characteristics (Cognitive Interviews)

From: Development of the Diabetes Injection Device Experience Questionnaire (DID-EQ) and Diabetes Injection Device Preference Questionnaire (DID-PQ)

Characteristic US UK Total Sample
N 15 5 20
Mean Age (years) 64.7 (7.5) 57.0 (7.8) 62.8 (8.1)
Gender (n, %)
 Female 10 (66.7%) 2 (40.0%) 12 (60.0%)
 Male 5 (33.3%) 3 (60.0%) 8 (40.0%)
Ethnic/Racial Background (n, %)
 White 11 (73.3%) 4 (80.0%) 15 (75.0%)
 Mixed 0 (0.0%) 0 (0.0%) 0 (0.0%)
 Asian 0 (0.0%) 1 (20.0%) 1 (5.0%)
 Black 1 (6.7%) 0 (0.0%) 1 (5.0%)
 Othera 3 (20.0%) 0 (0.0%) 3 (15.0%)
Marital Status (n, %)
 Single 1 (6.7%) 2 (40.0%) 3 (15.0%)
 Married/Living with partner 12 (80.0%) 2 (40.0%) 14 (70.0%)
 Otherb 2 (13.3) 1 (20.0%) 3 (15.0%)
Employment Status (n, %)
 Full-time work 2 (13.3%) 2 (40.0%) 4 (20.0%)
 Part-time work 4 (26.7%) 1 (20.0%) 5 (25.0%)
 Otherc 9 (60.0%) 2 (40.0%) 11 (55.0%)
Education Level (n, %)
 University degree 7 (46.7%) 2 (40.0%) 9 (45.0%)
 No University degree 8 (53.3%) 3 (60.0%) 11 (55.0%)
Interview Conducted
 In-Person (n) 0 (0.0%) 3 (60.0%) 3 (15.0%)
 Telephone (n) 15 (100.0%) 2 (40.0%) 17 (85.0%)
Current Medication
 GLP-1 15 (100.0%) 5 (100.0%) 20 (100.0%)
 Insulin 2 (13.3%) 0 (0.0%) 2 (10.0%)
 Pramlintide 1 (6.7%) 0 (0.0%) 1 (5.0%)
Current GLP-1
 Exenatide extended release (either pen or tray) 7 (46.7) 0 (0.0%) 7 (35.0%)
 Liraglutide 4 (26.7) 2 (40.0%) 6 (30.0%)
 Dulaglutide 3 (20.0%) 0 (0.0%) 3 (15.0%)
 Lixisenatide 0 (0.0%) 2 (40.0%) 2 (10.0%)
 Exenatide twice daily 0 (0.0%) 1 (20.0%) 1 (5.0%)
 Albiglutide 1 (6.7%) 0 (0.0%) 1 (5.0%)
 Pramlintide 0 (0.0%) 0 (0.0%) 0 (0.0%)
  1. aOther ethnic/racial background includes: Hispanic (total: n = 3; US: n = 3)
  2. bOther marital status includes: Separated (total: n = 3; UK: n = 1; US: n = 2)
  3. cOther employment status includes: Retired (total: n = 10; US: n = 8; UK: n = 2); homemaker (total: n = 1; US: n = 1)